Heart Failure Research
Heart failure, also known as congestive heart failure or CHF, is an inability of the heart to pump sufficient blood around the body.Heart failure typically occurs secondary to an existing pathology that alters cardiac function. Examples of syndromes that can precede heart failure include myocardial infarction, arrhythmia or infection. These can also cause dilated cardiomyopathy, a condition which accounts for approximately one third of all cases of heart failure. The pathogenesis of heart failure is cyclical and progressive; endogenous mechanisms, which are activated during heart failure in an attempt to counteract the symptoms, actually worsen cardiac function. Cardiac dysfunction, either systolic or diastolic, triggers a decrease in stroke volume and a resultant increase in cardiac output. In healthy individuals the body responds to decreases in cardiac output by initiating the renin-angiotensin-aldosterone system (RAAS) to promote fluid retention, and also by activating the sympathetic nervous system to cause peripheral vasoconstriction. Under normal circumstances this counteracts the imbalance in stroke volume, restoring cardiac output to normal levels. In patients with heart failure the increase in blood volume, together with the heightened peripheral resistance and elevated levels of circulating catecholamines, causes an increased load on the already weakened ventricles with each contraction, and the stroke volume does not return to normal levels. Repeated cycles of this process further weaken the ventricle walls, prompting ventricular hypertrophy and a decreased force of contraction.
Heart Failure Research Products Targets
- PI 3-kinase (22)
- Others (7)
- Mineralocorticoid Receptor (7)
- Angiotensin-Converting Enzyme (8)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Angiotensin AT2 Receptor (3)
- Angiotensin AT1 Receptor (9)
- NKCC (2)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
Products for Heart Failure Research - Page 13
- Cat.No. Product Name Information/Activity
-
BCC6092
AR-C 102222
253771-21-0
-
BCC7506
BYK 191023 dihydrochloride
Potent and selective inhibitor of iNOS
-
BCC6824
EIT hydrobromide
1071-37-0
-
BCC6862
2-Iminopiperidine hydrochloride
16011-96-4
-
BCC6837
S-Isopropylisothiourea hydrobromide
4269-97-0
-
BCC6791
(S)-Methylisothiourea sulfate
867-44-7
-
BCC5706
L-NIL hydrochloride
150403-89-7
-
BCC7057
1400W dihydrochloride
1400W dihydrochloride is a potent and selective inhibitor of human inducible NO synthase with Ki values of 7 nM.
-
BCC7647
ARL 17477 dihydrochloride
866914-87-6
-
BCC6770
3-Bromo-7-nitroindazole
3-Bromo-7-nitroindazole is a more potent and selective inhibitor of neuronal nitric oxide synthase (nNOS) than eNOS or inducible nitric oxide synthase (iNOS). 3-Bromo-7-nitroindazole affects the intercellular messenger nitric oxide (NO) synthesis throughout the body and brain.


